ClinicalTrials.gg
CompletedNCT05193916Updated May 28, 2024

A Phase II Clinical Trial of Chiglitazar for NASH

A Phase 2 interventional study of chiglitazar sodium tablets and Placebo in NASH, sponsored by Chipscreen Biosciences, Ltd.. Completed at 15 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-05-28.

Sponsored by Chipscreen Biosciences, Ltd. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
104
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The study is to evaluate the efficacy and safety of chiglitazar monotherapy in patients with non-clcoholic steatohepatitis (NASH).

Read the detailed description

The study is a non-invasive exploratory phase II trial in patients who were clinically diagnosed as non-alcoholic steatohepatitis (NASH) with liver fibrosis accompanied by elevated triglycerides (TG) and insulin resistance. The efficacy and safety of chiglitazar tablets 48mg and 64mg will be compared with placebo in the 18-week-treament.

02

Conditions studied

  • NASH
03

In context

Lead sponsor

Chipscreen Biosciences, Ltd. is the lead sponsor of 42 studies on the registry; 11 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Before any evaluation, an form voluntarily signed by the patient must be obtained;
  2. 18 -75 years old (at the time of screening visit V1), male or female;
  3. MRI-PDFF ≥ 8% ;
  4. Liver stiffness value ( LSM ) 7.0-11.0kPa ;
  5. Triglyceride ( TG ) ≥1.7mmol/L and ≤5.6 mmol/L;
  6. HOMA-IR ≥ 2.5 ;
  7. Serum Alanine aminotransferease () ≥ the during screening.

Exclusion criteria

Exclusion Criteria:

  1. Type 1 diabetes;
  2. Any of the following for type 2 diabetes:

    • ≥ 8.5% during screening
    • At the time of screening, ≥ 2 oral hypoglycemic drugs combinations
    • Receiving any of the following medications at screening: Thiazolidinediones (TZD) drugs, fibrates, glucagon-like peptide-1 (GLP-1) receptor agonists, insulin
  3. Existing other liver diseases or history of liver diseases
  4. History of or cerebrovascular accident;
  5. History of myocardial infarction, or coronary angioplasty or coronary artery bypass surgery, unstable angina, heart failure ( NYHA grade III / IV ), or signs of left ventricular hypertrophy, or serious arrhythmias ;
  6. During screening, blood pressure ≥ 160/100 mmHg ;
  7. Previous or planned ( during the study period) bariatric surgery;
  8. Liver transplantation history or planned liver transplantation;
  9. Liver show liver cirrhosis or clinically diagnosed as cirrhosis;
  10. Weight loss of more than 5% in 6 months before screening;
  11. History of edema of lower limbs or whole body;
  12. diagnosed as osteoporosis or any other known bone disease;
  13. Donated blood or lost blood >400 ml within 8 weeks before the first medication;
  14. With MRI scan ;
  15. In the past 5 years, there was a history of malignant tumors of any organ system;
  16. ( HIV ) test is positive;
  17. Heavy drinking of alcohol for more than 3 months in a year;
  18. Heavy smoking >30 per day within 1 year;
  19. History of drug abuse in 12 months;
  20. Drugs cumulatively for more than 1 month in the previous 3 months before screening, such as obeticholic acid ( OCA ), berberine;
  21. Drugs that may cause liver damage for more than 2 weeks within 1 year before screening;
  22. Patients received the following medications unless they have received a stable dose for at least 1 month before screening :Beta-blockers, thiazide diuretics, statins, niacin, ezetimibe, thyroid hormone;
  23. The calculated \< 60 mL/(min*1.73m\^2 );
  24. There is clinical evidence of liver decompensation or severe liver damage;
  25. Low density lipoprotein cholesterol (LDL-C) ≥ 3.4 mmol/L during screening ;
  26. \< 100×10\^9 /L ;
  27. Patient participating in other clinical trials of drugs or medical devices within 3 months prior to screening ;
  28. Pregnant or breastfeeding women.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
104 participants (actual)

Study arms

  • Experimental
    Chiglitazar low dose

    3 tablets of drug and 1 tablet of placebo p.o. per day

    Drug: chiglitazar sodium tablets

  • Experimental
    Chiglitazar high dose

    4 tablets p.o. per day

    Drug: chiglitazar sodium tablets

  • Placebo comparator
    control group

    4 placebo tablets p.o. per day

    Drug: Placebo

Interventions

  • the drugs will be given orally once a day

    Also known as: Bilessglu®, CS-038, Carfloglitazar

  • DrugPlacebo

    no active drug contained

    Also known as: simulant of chiglitazar

06

What researchers measure

Primary outcomes

  1. Percentage change from baseline to week 18 in liver fat content as measured by MRI using the proton density fat fraction (MRI-PDFF)

    center reading for the primary endpoint

    Time frame: 18 weeks

Secondary outcomes

  1. the change in liver fat content from baseline as shown by MRI-PDFF after 18 weeks treatment

    Absolute decrease in liver fat content Proportion of patients with Liver fat content absolute decrease ≥5% Proportion of patients with Liver fat content relative decrease ≥30% proportion

    Time frame: 18 weeks

  2. ALT changes from baseline

    changes from baseline in liver enzymes

    Time frame: 6,12,18 weeks

  3. FIB-4 changes from baseline

    changes from baseline in Fibrosis 4 Score

    Time frame: 6,12,18 weeks

  4. insulin resistance changes

    Homeostatic Model Assessment for Insulin Resistance (HOMA-IR)

    Time frame: 6,12,18 weeks

  5. Changes from baseline in TG

    blood sample

    Time frame: 6,12,18 weeks

  6. change from baseline in Liver stiffness measurement (LSM) with Fibroscan

    to evlaute the severity of liver fibrosis

    Time frame: 6,12,18 weeks

  7. change from baseline in Cytokeratin18 (CK-18)

    to evaluate the severity of liver damage

    Time frame: 6,12,18 weeks

  8. Maximum Plasma Concentration [Cmax] of chiglitazar after 1 dose, 6 weeks and 12 weeks of treatment

    population PK

    Time frame: 0, 6,12 weeks

  9. The area under the plasma drug concentration-time curve [AUC] of chiglitazar after 1 dose, 6 weeks and 12 weeks of treatment

    population PK

    Time frame: 0, 6,12 weeks

07

Study locations

15 sites
  • Beijing Friendship Hospital, Capital Medical University
    Beijing, Beijing 100050, China
  • Beijing Youan Hospital, Capital Medical University
    Beijing, Beijing, China
  • Peking University People's Hospital
    Beijing, Beijing, China
  • The First Hospital of Lanzhou University
    Lanzhou, Gansu, China
  • Foshan First People's Hospital
    Foshan, Guangdong, China
  • The First Affiliated Hospital of Sun Yat-sen University
    Guangzhou, Guangdong, China
  • Henan Provincial People's Hospital
    Zhengzhou, Henan, China
  • The First Affiliated Hospital of Anhui Medical University
    Hefei, Jiangsu, China
  • Nanjing Second Hospital
    Nanjing, Jiangsu, China
  • The First Hospital of Jilin University
    Ch'ang-ch'un, Jilin, China
  • The First Affiliated Hospital of Xi'an Jiaotong University
    Xi'an, Shaanxi, China
  • Shanghai Tongren Hospital
    Shanghai, Shanghai, China
  • The Ninth People's Hospital Affiliated to Shanghai Jiaotong University School of Medicine
    Shanghai, Shanghai, China
  • Affiliated Hospital of Hangzhou Normal University
    Hangzhou, Zhejiang, China
  • First Affiliated Hospital of Zhejiang University School of Medicine
    Hangzhou, Zhejiang, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2022 to primary completion in Jan 2024, 21 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 3, 2021
First posted
Jan 18, 2022
StartActual
Mar 21, 2022
Primary completionActual
Jan 2, 2024
CompletionActual
Jan 2, 2024
Last update
May 28, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 28, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05193916
Responsible party
Sponsor
First posted
Jan 18, 2022
Start date
Mar 21, 2022
Primary completion
Jan 2, 2024
Completion
Jan 2, 2024
Last update
May 28, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Chiglitazar

Start the discussion